Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 285-294

  Saint Marcoux, Franck ^a,b   Vandierdonck, Soizic ^a   Prémaud, Aurélie ^a   Debord, Jean ^a,b   Rousseau, Annick ^a   Marquet, Pierre ^a,b,c  

^a UNIVERSITY OF LIMOGES   (France)

^b Univ Limoges   (France)

^c Roche Pharma ^*  (France)

Author keywords

Bayesian estimation; Mycophenolate mofetil; Pharmacokinetic modeling; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AREA UNDER CURVE; BAYES THEOREM; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES;

EID: 80051785543     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821633a6     Document Type: Article

References (29)

1. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341-358.
2. Mourad M, Wallemacq P, König J, et al. Therapeutic drug monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet. 2002;41:319-327.
3. Shaw LM, Nawrocki A, Korecka M. et al. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit. 2004;26:347-351. (Pubitemid 38989652)
4. van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant. 2005;5:199-200. (Pubitemid 40179503)
5. van Gelder, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80(Suppl):S244-S253.
6. Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit. 2005;27:442-450. (Pubitemid 41098818)
7. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28: 145-154. (Pubitemid 44314941)
8. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006; 82:1004-1012. (Pubitemid 44632114)
9. de Winter BC, Mathôt RA, van Hest RM, et al. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin Drug Metab Toxicol. 2007;3:251-261. (Pubitemid 47316040)
10. Shaw LM, Figurski M, Milone MC, et al. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007;2:1062-1072.
11. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675-1685.
12. van Gelder T, Tedesco-Silva H, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the Fixed-Dose Concentration-Controlled Trial. Transplantation. 2008;86:1043-1051.
13. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503. (Pubitemid 47566324)
14. Premaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005;44:837-847. (Pubitemid 41126931)
15. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation ofmycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27:354-361. (Pubitemid 40770993)
16. Marquet P, Saint-Marcoux F, Prémaud A, et al. Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. Ther Drug Monit. 2009;31:443-450.
17. ImmunoSuppressants Bayesian dose Adjustment (ISBA). Available at: https://pharmaco.chu-limoges.fr. Accessed February 2011.
18. Proost JH, Eleveld DJ. Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res. 2006;23:2748-2759. (Pubitemid 44885363)
19. Steimer JL, Mallet A, Golmard JL, et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15:265-292. (Pubitemid 14123939)
20. Premaud A, Rousseau A, Le Meur Y, et al. Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. Pharmacol Res. 2010;61:167-174.
21. Bonate PL. The art of modelling. In: Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Lightning Source UK Ltd. Milton Keynes, UK: Elsevier Editions; 2006.
22. Prémaud A, Rousseau A, Picard P, et al. determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2006;28:274-277. (Pubitemid 44314962)
23. Brandhorst G, Marquet P, Shaw LM, et al. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Ther Drug Monit. 2008;30:428-433.
24. van Gelder T, Domke I, Engelmayer J, et al. Clinical utility of a new enzymatic assay for determination ofmycophenolic acid in comparison with an optimized LC-MS/MS method. Ther Drug Monit. 2009;31:218-7223.
25. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol. 1997;5:225-232. (Pubitemid 27489255)
26. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539. (Pubitemid 29468321)
27. Picard N, Premaud A, Rousseau A, et al. A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol. 2006;62:477-484. (Pubitemid 44401531)
28. Smak Gregoor P, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999;14:706-708. (Pubitemid 29106002)
29. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035. (Pubitemid 38669688)